FindTrial
Sign In

Use of ketofol (ketamine pluse propofol) in modified ECT as compair to propofol alone in modified ECT in terms of seizure duration, haemodynamic stability and adverse events if any.

A prospective randomised double-blinded study on comparision of propofol and ketofol(combination of ketamine and propofol) for modified electroconvulsive therapy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032916
Enrollment
60
Registered
2021-04-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Injection KETOFOL 10mg/ml.: By using inj KETOFOL 10mg/ml(Ketamine:propofol 1:1 Ratio) i.e. Ketamine 5mg/ml and propofol 5mg/ml in lower doses to provide rapid onset, short duration and

Sponsors

JLN medical college ajmer
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 to 60 years of either sex undergoing modified ECT. 2. ASA I and II grades. 3. Modified ECT under general anaesthesia. 4. Informed written consent.

Exclusion criteria

Exclusion criteria: 1. History of any serious physical disease, such as cardiovascular disease, cerebrovascular disorder, intracranial hypertension, respiratory tract disease, and severe fracture. 2. Hypertension, glaucoma, arterial aneurysm, or cerebrovascular malformation. 3. Presence of a foreign body, such as a pacemaker, intracranial electrode, and clips. 4. History of seizures and those using anticonvulsant drugs. 5. History of substance abuse or dependence, including alcohol abuse. 6. ASA III,IV,V status. 7. Hypersensitivity to any study drug. 8. Pregnancy.

Design outcomes

Primary

MeasureTime frame
The primary outcome of our study will be to assess duration of seizure activity (from the time of administration of electrical stimuli to the time of end of seizure in isolated arm).Timepoint: Duration of study is around 1 year—

Secondary

MeasureTime frame
Secondary outcome will be assessment of Hemodynamic changes, recovery parameters, adverse events, if any in modified ECT. Timepoint: Duration of study is around 1 year—

Countries

India

Contacts

Public ContactDr Veena mathur

Jawahar lal nehru medical college, ajmer, rajasthan

veenamathur41@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026